Enhance Further Strenghtens Development Experience on Science Team.

Business Editors/Health/Medical Writers

NEW YORK--(BUSINESS WIRE)--Sept. 17, 2003

Enhance Biotech, Inc. (OTCBB:EBOI) today announced the appointment of Dr. Malcolm Thomas as a member of the science team and participant on the science advisory board.

Dr. Thomas brings

Chris Every, CEO of Enhance Biotech stated, "We are delighted that Malcolm has joined us and will be adding his skills and experience in early stage development to those of our Chief Scientific Officer, Dr. Sam McCormick. Malcolm's more recent experience in the U.S. and European environments will add considerable value to the team as we go forward. We have now created a formidable team to shepard our product pipeline program forward."

"I am enthusiastic about the Enhance portfolio of products and practical approach to development. I look forward to the opportunity to apply my medical experience and years of international pharmaceutical development to help bring the products to the global market," stated Dr. Thomas.

Dr. Thomas is a successful drug development manager with transatlantic experience, particularly in Proof of Concept trials up through and including Phase II studies in a number of different therapeutic areas. Following early roles in development at Parke Davis and Fisons, Dr. Thomas successfully managed the development programs of Glaxo/Glaxo Wellcome, as Director of Pharmacology at both their U.K. and U.S. Research Triangle sites. Recently he has successfully operated in both regions as an independent advisor on drug development involved in a wide range of compounds and developments, experiencing a valuable array of methods and approaches to the process of drug development. This valuable expertise and skill base is underpinned by a foundation of medical practice in leading U.K. hospitals such as St. Bartholomew's and University College Hospital London as well as working as a general practioner in the community.

About Enhance Biotech

Enhance Biotech Inc is a Holding company for its wholly owned subsidiary Enhance Lifesciences Inc. The product portfolio focuses upon seven key areas of the lifestyle market some of which are development platforms with potential for ongoing development indications too. The key areas are; Sexual dysfunction, Anti-aging, Depression, Cellulite, Fertility, Arthritis, and Skin Disorders. Enhance's products are each licensed in at later stages of development and will be taken on through development and approval to market, adding significant value to each in the immediate future. This creates a valuable product pipeline portfolio in a market forecast to grow to US$29 billion by 2007. A market where the pharmaceutical industry has invested over $20 billion in lifestyle drugs R&D in the last ten years although relatively few new products have reached market as yet. Enhance Lifescience's lead development products fill an unmet need in a global blockbuster market. The Management and Science Team have a proven track record of successful development and commercialization of new products and the licensing out of valuable intellectual property. For more information on the company please see the company's website at www.enhancelifesciences.com

Certain statements contained herein are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because these statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Specifically, factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to: risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and in Enhance Biotech's compounds under development in particular; the potential failure of Enhance Biotech's compounds under development to prove safe and effective for treatment of disease; uncertainties inherent in the early stage of Enhance Biotech' compounds under development; failure to successfully implement or complete clinical trials; failure to receive marketing clearance from regulatory agencies for our compounds under development; acquisitions, divestitures, mergers, licenses or strategic initiatives that change Enhance Biotech' business, structure or projections; the development of competing products; uncertainties related to Enhance Biotech' dependence on third parties and partners; and those risks described in the filings with the SEC, all of which are under the Company's prior name Becor Communications, Inc. The Company and Enhance Biotech disclaim any obligation to update these forward-looking statements.